Biophytis (EPA:ALBPS)

REGULATED PRESS RELEASE

published on 07/15/2025 at 07:00, 8 months 25 days ago

Biophytis Partners in AI with Lynx Analytics to Accelerate Drug Discovery for Sarcopenia
Biophytis partners with Lynx Analytics to accelerate drug discovery for sarcopenia through AI collaboration. The partnership aims to develop small molecule drugs for muscle preservation and regeneration

Biophytis Drug Discovery AI Sarcopenia Lynx Analytics
BRIEF

published on 07/11/2025 at 08:19, 8 months 29 days ago

Biophytis Reports 2024 Financial Results and Strategy for 2025

Drug Discovery Partnerships Biophytis Financials 2025 Strategic Plans Phase 2 And Phase 3 Trials
REGULATED PRESS RELEASE

published on 07/11/2025 at 08:14, 8 months 29 days ago

Biophytis Reports 2024 Financial Results and 2025 Outlook
Biophytis announces 2024 financial results, 2025 outlook. Initiates Phase 2 study in obesity, Phase 3 study in sarcopenia. Strengthens drug discovery platform. Resumes trading on Euronext Growth Paris

Financial Results Biophytis Drug Discovery Phase 3 Phase 2
BRIEF

published on 07/08/2025 at 07:05, 9 months 1 day ago

Biophytis Highlights Longevity Innovation at ARC 2025

Innovation Biophytis Longevity Sarcopenia ARC 2025
REGULATED PRESS RELEASE

published on 07/08/2025 at 07:00, 9 months 1 day ago

Biophytis at the Forefront of Longevity Innovation at the World Aging & Rejuvenation Conference 2025
Biophytis SA announces participation in ARC 2025 to present results of BIO101 in sarcopenia at the World Aging & Rejuvenation Conference, aiming to strengthen scientific visibility and expand in the longevity market

Sarcopenia Biophytis SA BIO101 Longevity Market ARC 2025
BRIEF

published on 07/07/2025 at 07:05, 9 months 2 days ago

Biophytis Aims to Address Muscle Loss in Obesity Market

Biophytis BIO101 Muscle Preservation GLP-1 Therapies Obesity Market
REGULATED PRESS RELEASE

published on 07/07/2025 at 07:00, 9 months 2 days ago

Obesity: Biophytis Charts Its Course Toward a Booming Market
Biophy.s SA is focusing on developing transformative therapies for obesity, sarcopenia, and longevity by addressing muscle loss with its lead drug BIO101. The company's strategic positioning targets the expanding obesity market

BIO101 Obesity Market Opportunity Muscle Loss Biophy.s SA
BRIEF

published on 07/03/2025 at 07:05, 9 months 6 days ago

Biophytis Showcases Innovations at BIO International 2025

Biophytis Precision Medicine Longevity Sarcopenia Obesity Therapy
REGULATED PRESS RELEASE

published on 07/03/2025 at 07:00, 9 months 6 days ago

Biophythis Powers Innovation in Obesity, Muscle Health, and Longevity at BIO International 2025
Biophytis highlights innovations in obesity, muscle health, and longevity at BIO International 2025, showcasing therapies targeting key health challenges. Strategic partnerships post-conference aim to accelerate therapies' global impact

Innovations Longevity Obesity Muscle Health Biophy(s
BRIEF

published on 06/30/2025 at 22:35, 9 months 9 days ago

Biophytis Delays Publication of 2024 Annual Financial Statements

Biophytis Biotechnology Drug Development Annual Accounts Financial Delay

Published on 04/10/2026 at 02:15, 33 minutes ago

Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates
Published on 04/10/2026 at 01:05, 1 hour 43 minutes ago

Pathfinder Ventures Inc. Announces Tranche Closing of Financing and Extension of Private Placement
Published on 04/10/2026 at 00:00, 2 hours 48 minutes ago

Redwood AI Announces Upgraded Cloud-Based Reactosphere Platform with Enhanced Security and Expanded Core Capabilities
Published on 04/09/2026 at 23:15, 3 hours 33 minutes ago

Digi Power X Enters into Amended and Restated Sales Agreement
Published on 04/09/2026 at 23:05, 3 hours 43 minutes ago

Caldwell Reports Second Quarter Results

View all ACCESSWIRE

Published on 04/09/2026 at 22:00, 4 hours 48 minutes ago

Invitation - First Quarter 2026 Trading Update Conference Call
Published on 04/09/2026 at 21:01, 5 hours 47 minutes ago

GEVELOT S.A.: PRESS RELEASE CLOSING OF 2025 ACCOUNTS
Published on 04/09/2026 at 20:03, 6 hours 45 minutes ago

Annual General Meeting approves all proposals
Published on 04/09/2026 at 18:15, 8 hours 33 minutes ago

REPLY: Launch of a share buyback program for a maximum number of 3,607,950 shares
Published on 04/09/2026 at 15:59, 10 hours 49 minutes ago

Cairn Homes Plc: Holding(s) in Company

View all EQS

Published on 04/09/2026 at 18:35, 8 hours 13 minutes ago

Availability of proxy documents for the Combined General Meeting of April 30, 2026
Published on 04/09/2026 at 17:35, 9 hours 13 minutes ago

SUEZ - FY 2025
Published on 04/09/2026 at 15:57, 10 hours 51 minutes ago

Filing of CNP Assurances SA 2025 universal registration document and 2025 Solvency and Financial Condition Reports
Published on 04/09/2026 at 07:00, 19 hours 48 minutes ago

bioMérieux Unveils its BIOFIRE® SPOTFIRE® Molecular Testing Solution for the Pharmaceutical Industry, Redefining Rapid Mycoplasma Testing
Published on 04/08/2026 at 18:02, 1 day 8 hours ago

Publication of the 2025 Universal Registration Document

View all LES ECHOS COMFI WIRE

News